The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

peanut allergy

This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years. The patch is a form of epicutaneous immunotherapy (EPIT), which is a new approach to allergen immunotherapythat delivers a small amount of peanut protein to the immune system through the skin

22nd Jan 2024

A plain language summary of epicutaneous immunotherapy with Viaskin™ Peanut in toddlers